Sionna Therapeutics Inc

Discover how Sionna Therapeutics’ insider buying and selling signals confidence yet reveals market challenges, and what this means for investors and future growth.

TPG’s $40/share sale of 250k Sionna units shows a liquidity‑driven shift that may boost partnership talks, but investors must watch Phase‑2 results to gauge long‑term impact.

TPG sells 250k Sionna shares at $40 each—no impact on holdings, but watch galicaftor and navocaftor Phase II results that could boost valuation.